Inhibition of angiogenesis and the angiogenesis/invasion shift

Biochemical Society Transactions

Volumn 39, Issue 6, 2011, Pages 1560-1564

  Bikfalvi, Andreas ^a,b   Moenner, Michel ^a,b   Javerzat, Sophie ^a,b   North, Sophie ^a,b   Hagedorn, Martin ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

Author keywords

Angiogenesis; Chemokine; Combinatorial therapy; Resistance to anti angiogenesis therapy; Stress response; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; DECORIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; OSTEONECTIN; PROTEIN IRE1; THROMBOSPONDIN 1; TOCILIZUMAB;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER INVASION; CANCER RESISTANCE; CELL INFILTRATION; CELLULAR STRESS RESPONSE; CHORIOALLANTOIS; CONFERENCE PAPER; GENE SILENCING; GLIOBLASTOMA; HUMAN; ISCHEMIA; MALIGNANT TRANSFORMATION; METASTASIS INHIBITION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-6; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 81855218092     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20110710     Document Type: Conference Paper

References (29)

1. Carmeliet, P. and Jain, R.K. (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307
2. Algire, G.H. and Chalkley, H.W. (1945) Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic implants. J. Natl. Cancer Inst. 6, 73-85
3. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186
4. Ferrara, N., Mass, R.D., Campa, C. and Kim, R. (2007) Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 58, 491-504 (Pubitemid 46706529)
5. Semenza, G.L. (2011) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634
6. Kerbel, R.S. (2008) Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049
7. Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D. and Casanovas, O. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231
8. Ebos, J.M., Lee, C.R. and Kerbel, R.S. (2009) Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res. 15, 5020-5025
9. Ebos, J.M. and Kerbel, R.S. (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221
10. Saidi, A., Javerzat, S., Bellahcène, A., De Vos, J., Bello, L., Castronovo, V., Deprez, M., Loiseau, H., Bikfalvi, A. and Hagedorn, M. (2008) Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int. J. Cancer 122, 2187-2198 (Pubitemid 351542321)
11. Ferrara, N. (2010) Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr. Opin. Hematol. 17, 219-224
12. Hagedorn, M., Javerzat, S., Gilges, D., Meyre, A., de Lafarge, B., Eichmann, A. and Bikfalvi, A. (2005) Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc. Natl. Acad. Sci. U.S.A. 102, 1643-1648 (Pubitemid 40209221)
13. Saidi, A., Hagedorn, M., Allain, N., Verpelli, C., Sala, C., Bello, L., Bikfalvi, A. and Javerzat, S. (2009) Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int. J. Cancer 125, 1054-1064
14. Ron, D. and Hubbard, S.R. (2008) How IRE1 reacts to ER stress. Cell 132, 24-26
15. Drogat, B., Auguste, P., Nguyen, D.T., Bouchecareilh, M., Pineau, R., Nalbantoglu, J., Kaufman, R.J., Chevet, E., Bikfalvi, A. and Moenner, M. (2007) IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res. 67, 6700-6707 (Pubitemid 47105516)
16. Drogat, B., Bouchecareilh, M., North, S., Petibois, C., Déléris, G., Chevet, E., Bikfalvi, A. and Moenner, M. (2007) Acute L-glutamine deprivation compromises VEGF-A upregulation in A549/8 human carcinoma cells. J. Cell. Physiol. 212, 463-472 (Pubitemid 47025636)
17. Auf, G., Jabouille, A., Guérit, S., Pineau, R., Delugin, M., Bouchecareilh, M., Magnin, N., Favereaux, A., Maitre, M., Gaiser, T. et al. (2010) Inositol-requiring enzyme 1α is a key regulator of angiogenesis and invasion in malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 107, 15553-15558
18. Keeley, E.C., Mehrad, B. and Strieter, R.M. (2008) Chemokines as mediators of neovascularization. Arterioscler. Thromb. Vasc. Biol. 28, 1928-1936
19. Aidoudi, S., Bujakowska, K., Kieffer, N. and Bikfalvi, A. (2008) The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS ONE 3, e2657
20. Ragona, L., Tomaselli, S., Quemener, C., Zetta, L. and Bikfalvi, A. (2009) New insights into the molecular interaction of the C-terminal sequence of CXCL4 with fibroblast growth factor-2. Biochem. Biophys. Res. Commun. 382, 26-29
21. Lozano, R.M., Redondo-Horcajo, M., Jimenez, M.A., Zilberberg, L., Cuevas, P., Bikfalvi, A., Rico, M. and Giménez-Gallego, G. (2001) Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity. J. Biol. Chem. 276, 35723-35734
22. Perollet, C., Han, Z.C., Savona, C., Caen, J.P. and Bikfalvi, A. (1998) Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 91, 3289-3299 (Pubitemid 28193879)
23. Jouan, V., Canron, X., Alemany, M., Caen, J.P., Quentin, G., Plouet, J. and Bikfalvi, A. (1999) Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 94, 984-993 (Pubitemid 29361830)
24. Hagedorn, M., Zilberberg, L., Lozano, R.M., Cuevas, P., Canron, X., Redondo-Horcajo, M., Gimenez-Gallego, G. and Bikfalvi, A. (2001) A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 15, 550-552
25. Lasagni, L., Francalanci, M., Annunziato, F., Lazzeri, E., Giannini, S., Cosmi, L., Sagrinati, C., Mazzinghi, B., Orlando, C., Maggi, E. et al. (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197, 1537-1549 (Pubitemid 36682550)
26. Struyf, S., Burdick, M.D., Proost, P., Van Damme, J. and Strieter, R.M. (2004) Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ. Res. 95, 855-857 (Pubitemid 39434999)
27. Lasagni, L., Grepin, R., Mazzinghi, B., Lazzeri, E., Meini, C., Sagrinati, C., Liotta, F., Frosali, F., Ronconi, E., Alain-Courtois, N. et al. (2007) PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 109, 4127-4134 (Pubitemid 46743373)
28. Dubrac, A., Quemener, C., Lacazette, E., Lopez, F., Zanibellato, C., Wu, W.G., Bikfalvi, A. and Prats, H. (2010) Functional divergence between 2 chemokines is conferred by single amino acid change. Blood 116, 4703-4711
29. Cervi, D., Yip, T.T., Bhattacharya, N., Podust, V.N., Peterson, J., Abou-Slaybi, A., Naumov, G.N., Bender, E., Almog, N., Italiano, Jr, J.E. et al. (2008) Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111, 1201-1207 (Pubitemid 351213401)